Jameson Pawlik, PA
Medical · Sarasota, FLNPI 1174749212
Payments from drug & device makers
Across 121 payments — averaging $29.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$830
- AbbVie$556
- Novartis$363
- Organogenesis Inc.$339
- Revance Therapeutics, Inc.$329
- Sun Pharmaceutical Industries Inc.$195
- plus $992 from 15 others
What the payments were for
- Food & beverage$3,50497%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 11 | $830 |
| AbbVie | 26 | $556 |
| Novartis | 16 | $363 |
| Organogenesis Inc. | 14 | $339 |
| Revance Therapeutics, Inc. | 6 | $329 |
| Sun Pharmaceutical Industries Inc. | 6 | $195 |
| Regeneron Healthcare Solutions, Inc. | 7 | $194 |
| Amgen | 4 | $113 |
| Incyte Corporation | 5 | $113 |
| Lilly USA, LLC | 5 | $113 |
| Sanofi | 3 | $78 |
| Pfizer | 3 | $68 |
| Kerecis Limited | 1 | $63 |
| Johnson & Johnson | 4 | $59 |
| UCB, Inc. | 2 | $44 |
| Convatec Inc. | 2 | $42 |
| LEO Pharma Inc. | 1 | $28 |
| Biofrontera Inc. | 2 | $24 |
| Dermavant Sciences, Inc. | 1 | $24 |
| Galderma Laboratories, L.p. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,604 in reported general payments places this provider in the 80th percentile of 2,031 medical providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 13 | $44,642 |
| Fluorouracil | 83 | $5,074 |
| Betamethasone Dipropionate | 99 | $4,189 |
| Clobetasol Propionate | 21 | $988 |
| Ketoconazole | 45 | $905 |
| Doxycycline Hyclate | 74 | $882 |
| Triamcinolone Acetonide | 48 | $376 |
| Mupirocin | 47 | $267 |
| ValacyclovirValacyclovir Hcl | 13 | $231 |
| Cephalexin | 11 | $179 |
| Nystatin | 21 | $152 |
Paid to pharmacies, not to this prescriber.
Other medical in Sarasota
- Matthew JohnsonSarasota$16K
- Jesse LebaronSarasota$16K
- Amy TraSarasota$16K
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
- Erin DouceyWinter Haven$202K
- Kathleen TrummerWellington$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.